Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.
During the last years, more and more treatment modalities are available for MDS patients. Therefore, we were interested if this is reflected in an improvement of the outcome of the patients. We analyzed the survival and rate of leukemic progression of 4147 patients from the Duesseldorf MDS registry diagnosed during the last 30 years and found an improvement of survival in those patients diagnosed after 2002 (30 vs. 23 months, p<0.0001). In detail, the improvement of the prognosis was restricted to high-risk MDS patients diagnosed between 2002 and 2014 in comparison to the patient group diagnosed between 1982 and 2001 (19 vs. 13 months, p<0.001), whereas the prognosis of low-risk MDS patients did not change significantly. The improvement of survival was still measurable after exclusion of RAEB-t patients and of those, that received an allogeneic stem cell transplantation. In line with this finding, we found a lower AML progression rate in the later diagnosed group. Unfortunately, we could not identify a clear reason for this finding but rather a multifactorial cause should be assumed. As death due to bleeding complications and infections was significantly lower, an improvement of BSC may be one of the underlying causes.
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany. Electronic address: Judith.Neukirchen@med.uni-duesseldorf.de.
Judith
J
Neukirchen
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Kathrin
K
Nachtkamp
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Jennifer
J
Schemenau
Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
Carlo
C
Aul
Department of Oncology, Hematology and Palliative Care, Marienhospital, Duesseldorf, Germany.
Aristoteles
A
Giagounidis
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Corinna
C
Strupp
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Andrea
A
Kuendgen
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Guido
G
Kobbe
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Rainer
R
Haas
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Ulrich
U
Germing
D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
AML; BSC; MDS; Prognosis; Survival; Treatment